Carbidopa And Levodopa NDC 16729-078

NDC codes

FDA NDC Directory

Product NDC (as listed)16729-078Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16729-0078Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16729-078-01	16729007801	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-078-01)Marketed from Jun 13, 2013
16729-078-17	16729007817	1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (16729-078-17)Marketed from Oct 31, 2013

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carbidopa And Levodopa
Generic name (nonproprietary): carbidopa and levodopa
Active ingredients: Carbidopa — 25 mg/1Levodopa — 100 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Accord Healthcare, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202323
Marketing start: Jun 13, 2013
Listing expires: Dec 31, 2026
Other FDA classes: Aromatic (Chemical structure)
Identifiers: Product ID 16729-078_40a9fe53-d24b-d4ad-e063-6294a90aeff5SPL ID 40a9fe53-d24b-d4ad-e063-6294a90aeff5SPL set ID 5217a6ec-cc26-4acc-b2da-17f6545c3b60RxCUI 308988, 308989UNII 46627O600J, MNX7R8C5VO
Pharmacologic class: Aromatic Amino Acid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N416729007801 followed by a unit qualifier and the quantity

Package 16729-0078-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 8, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202323

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202323
Product	Strength	Form · route	Labeler	Product NDC
Carbidopa And Levodopa	Carbidopa 50 mg/1; Levodopa 200 mg/1	Tablet, Extended releaseOral	Accord Healthcare, Inc.	16729-079